András Rosta

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

Joseph M. Connors, Wojciech Jurczak, David J. Straus et al. · New England Journal of Medicine · 2017 · 764 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

Tadeusz Robak, Anna Dmoszyńska, Philippe Solal‐Céligny et al. · Journal of Clinical Oncology · 2010 · 475 citations · Full text

Medicine, Immunology, Oncology +16

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 159 citations · Full text

Medicine, Immunology, Oncology +13

Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

Tadeusz Robak, Moiseev Si, Anna Dmoszyńska et al. · Blood · 2008 · 68 citations

Medicine, Oncology, Pharmacotherapy +16

Putative Role of Dihydropyrimidine Dehydrogenase in the Toxic Side Effect of 5-Fluorouracil in Colorectal Cancer Patients

Csilla Katona, Judit Kralovánszky, András Rosta et al. · Oncology · 1998 · 52 citations

Medicine, Oncology, Pharmacology +13